Several preclinical studies demonstrated how dapagliflozin reduces ROS production and enhances the antioxidant defence system (SOD2, GPx4) in both in vitro and in vivo models of DOX‐induced cardiotoxicity and HF.113, 114, 115. This evidence concerns the gene GPX4 and hydrops fetalis.